Results for this period
Full year1 July 2025 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from life science research support services decreased due to a decline in large-scale projects in Japan's academic sector and weaker demand in overseas markets. Revenue from functional materials development support services increased on strong orders for products including health-claim measurement packages. Bio-based manufacturing support services received strong orders following commercialization. Cost of sales was affected by increases in depreciation and repair expenses, while selling, general and administrative expenses were affected by a decrease in development expenses following the completion of joint research projects and other factors.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 30 June 2026 |
| Net Sales | ¥1,421 million (YoY -2.3%) |
| Operating profit | ¥209 million (YoY -15.9%) |
| Ordinary income | ¥206 million (YoY -14.2%) |
| Profit attributable to owners of the parent | ¥200 million (YoY -21.9%) |
| Net income per share | ¥35.70 |
| Operating Margin | 14.8% |
| Equity ratio | End of the current fiscal period 80.2% / End of previous period 79.6% |
| Total assets | ¥2,280 million |
| Net assets | ¥1,828 million |
| Cash flows from operating activities | ¥208 million |
| Cash flows from investing activities | ¥-83 million |
| Cash flows from financing activities | ¥-281 million |
| Cash and cash equivalents at end of period | ¥1,444 million |
| Full-year earnings forecast | Net Sales ¥1,500 million (YoY +5.5%) / Operating profit ¥220 million (YoY +4.8%) / Ordinary income ¥220 million (YoY +6.4%) / Net income ¥170 million (YoY -15.2%) |
| Annual Dividend Forecast | ¥15 → ¥18（+20.0%） |
| Payout ratio | 57.4% |
| Regional sales | Fiscal year ending June 2026 Japan ¥1,342,685 thousand / Europe and North America ¥59,362 thousand / Asia ¥19,897 thousand / Fiscal year ended June 2025 Japan ¥1,304,099 thousand / Europe and North America ¥119,234 thousand / Asia ¥31,670 thousand |
| Depreciation and amortization | ¥111,348 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥17,993 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (institutional investors and analysts) |
| Issued Shares at Period-End | 5,919,797 shares |
| Treasury Shares at Period-End | 500,018 treasury shares |
| Factors Behind Changes in Business Performance | Revenue from life science research support services decreased due to a decline in large-scale projects in Japan's academic sector and weaker demand in overseas markets. Revenue from functional materials development support services increased on strong orders for products including health-claim measurement packages. Bio-based manufacturing support services received strong orders following commercialization. Cost of sales was affected by increases in depreciation and repair expenses, while selling, general and administrative expenses were affected by a decrease in development expenses following the completion of joint research projects and other factors. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from life science research support services decreased due to a decline in large-scale projects in Japan's academic sector and weaker demand in overseas markets. In contrast, functional materials development support services benefited from strong orders, while bio-based manufacturing support services received strong orders following commercialization. On the earnings side, depreciation and repair expenses increased, while development expenses decreased due to the completion of joint research projects and other factors.